evipedia.ai
← Back

Chamomile for Health & Longevity

Evidence Review created on 09/18/2026 using AI4L / Opus 5

Also known as: Matricaria chamomilla, Matricaria recutita, Chamomilla recutita, German Chamomile, Hungarian Chamomile, True Chamomile, Chamaemelum nobile, Anthemis nobilis, Roman Chamomile, English Chamomile

Motivation

Chamomile is the dried flower head of a small plant in the daisy family, brewed as a tea for thousands of years and now also sold as a measured oral extract. Its best-studied ingredient, apigenin, attaches to the same calming docking site in the brain that several prescription sedatives act on, which is how a traditional household preparation entered controlled clinical research.

Chamomile appears in ancient Egyptian, Greek, Roman and Chinese medical writing, and it remains one of the most widely consumed herbal teas in the world. Modern work has clustered around three claims: that it eases anxiety, that it improves sleep quality, and that it lowers blood sugar. Reviews that combine the trials now exist for each, and they do not all agree.

This review examines what the human evidence supports for chamomile as tea, oral extract, mouth rinse and topical oil. It sets out the mechanisms proposed for its effects, grades the strength of the evidence behind each claimed benefit and each reported harm, describes the doses used in trials, and identifies the interactions, allergy risks and product-quality issues that shape how that evidence applies.

Benefits - Risks - Protocol - Conclusion

High-level overviews of chamomile and of apigenin, its principal flavone, from expert platforms and the narrative-review literature.

  • Superfoods: Chamomile Tea - Laurie Mathena

    A compact overview of chamomile tea’s flavonoid content and its reported sleep and blood-sugar effects, useful as orientation to the claims tested below. Published by a supplement retailer.

  • Do Magnesium, Apigenin, and L-Theanine Improve Sleep? - Rhonda Patrick

    Patrick weighs the evidence for apigenin, chamomile’s principal flavone and the compound behind its calming reputation, and concludes that direct human sleep data for isolated apigenin remain sparse.

  • Sleep Toolkit: Tools for Optimizing Sleep & Sleep-Wake Timing - Andrew Huberman

    A podcast episode whose supplement segment covers apigenin, chamomile’s principal flavone, giving a specific bedtime dose and its proposed action on the brain’s main calming receptor.

  • Apigenin: Benefits And Side Effects - Steve Hill

    Reviews apigenin, chamomile’s principal flavone, covering its concentration in chamomile tea, the insomnia and anxiety trials, and the cellular-aging work that underpins chamomile’s longevity claims.

  • Chamomile: A herbal medicine of the past with bright future - Srivastava et al., 2010

    A narrative review of chamomile’s constituents, traditional indications and preclinical pharmacology; the standard entry point to the plant chemistry behind the clinical claims examined here.

Note on priority platforms: no substantive chamomile or apigenin content was found on peterattiamd.com, where the site’s own search returns no results and chamomile appears only in a reader comment beneath a cardiovascular article. chriskresser.com returns seven pages naming chamomile, but each treats it as one entry in a longer herb list or as one example among many phytochemicals, so none gives sustained coverage. Neither platform meets the depth bar, so the fifth slot went to a narrative review instead.

Grokipedia

  • Chamomile

    Covers both species, the etymology, the essential-oil and flavonoid chemistry, and the traditional-to-clinical arc, with the allergy and pet-toxicity caveats stated up front.

Examine

  • Chamomile

    Grades chamomile’s outcomes from 1,478 participants across one trial and three meta-analyses, rating blood glucose A and long-term blood sugar B, which is the most explicit evidence scoring available anywhere.

ConsumerLab

No dedicated ConsumerLab article or product review for chamomile exists. Chamomile appears only as a sub-section inside broader member articles on sleep and insomnia supplements, on apigenin, on pre-surgical supplement withdrawal and on anticoagulant (clot-slowing medicine) interactions, plus a 2022 regulatory warning about a chamomile tea marketer. None of these is a primary, dedicated chamomile page, and all sit behind the member paywall, so no link is given here.

Systematic Reviews

Pooled analyses of chamomile’s anxiety, sleep, glycemic and anti-inflammatory claims, plus the systematic appraisal of its reported harms.

Trade-off coverage: the benefit side is represented by four intervention-specific reviews, and the harm side by the fifth, which covers both the mild treatment-emergent events and the allergic reactions. No systematic review or meta-analysis covers pyrrolizidine-alkaloid (liver-toxic plant compound) contamination of chamomile products, and the bleeding risk is appraised only inside a broader multi-herb warfarin review rather than a chamomile-specific one, so those two harms are the least represented at this evidence tier and are handled from primary reports below.

Mechanism of Action

Chamomile’s activity is attributed to a mixture rather than a single molecule. The flowers carry flavones, chiefly apigenin and its 7-O-glucoside, plus luteolin and quercetin, and an essential oil containing alpha-bisabolol, its oxides, and chamazulene formed from matricin during extraction.

The calming effect is traced to apigenin binding the benzodiazepine site of the GABA-A receptor (GABA is the brain’s main inhibitory, or calming, chemical signal, GABA-A is the channel it opens, and benzodiazepines are the prescription sedative and anti-anxiety class that docks at the same point). Apigenin binds there weakly and reduced anxiety behaviour in mice without sedation (Viola et al., 1995). A competing reading has it reducing GABA-activated currents, with the slowing it causes in rats surviving benzodiazepine-site blockade (Avallone et al., 2000). The anti-inflammatory effect is attributed instead to the terpenoids and flavones dampening NF-κB signalling (a master switch that turns on inflammatory genes) and the cyclo-oxygenase and lipoxygenase enzymes downstream of it (which make inflammatory messengers).

Pharmacologically, apigenin itself is poorly absorbed, but the glucoside form in chamomile tea is not: in healthy men, the plasma metabolite apigenin-4’-glucuronide peaked about two hours after chamomile tea, indicating upper-gut absorption, with urinary recovery of 34% of intake, against 11% from a parsley drink (Borges et al., 2022). Clearance is by glucuronidation and sulfation rather than oxidation, so no cytochrome P450 enzyme (the liver’s main drug-oxidising family) is the primary route. Competing explanation: the warm-drink ritual and expectancy, not the chemistry, may carry much of the observed calming effect.

Historical Context & Evolution

Chamomile’s original use was medicinal rather than culinary. It is named in Egyptian, Greek, Roman and Chinese medical texts, was one of the nine sacred herbs of the Anglo-Saxons, and entered the pharmacopoeias of 26 countries as a cramp-relieving sedative for digestive and rheumatic complaints, a wound wash, and an inhalant for airway irritation.

Its modern re-entry into health optimization came from two directions. German phytotherapy formalised the traditional indications: Commission E approved German chamomile flower for skin and mucous-membrane inflammation, gastrointestinal spasm and inflammatory gut disease, as summarised in a drug monograph. Separately, the 1995 identification of apigenin as a central benzodiazepine-site ligand gave the folk sedative a receptor target, which made it testable.

What the historical research actually found matters here. The early pharmacology reported sedation, anticonvulsant activity and smooth-muscle relaxation in animals at doses far above dietary exposure, not clinical anxiety relief in people. Later human trials then split. The 2019 pooled analysis found benefit for sleep quality and generalized anxiety (Hieu et al., 2019); the 2022 World Federation of Societies of Biological Psychiatry and Canadian Network for Mood and Anxiety Treatments taskforce rated chamomile “not currently recommended” for generalized anxiety disorder (Sarris et al., 2022). That taskforce is a professional-society body whose members disclose pharmaceutical consultancies and whose standing rests on conventional psychopharmacology, so its rating is a claim to be weighed, not a verdict; the underlying trials remain positive on their own primary endpoints.

Expected Benefits

High 🟩 🟩 🟩

Reduced Anxiety Symptoms ⚠️ Conflicted

Standardized oral chamomile extract lowered anxiety on the Hamilton Anxiety Rating Scale (HAM-A, a clinician-scored anxiety scale) in an 8-week placebo-controlled trial of 57 outpatients with generalized anxiety disorder (GAD, persistent excessive worry) (Amsterdam et al., 2009) and in a 26-week continuation trial of 93 responders (Mao et al., 2016). The proposed mechanism is apigenin acting at the GABA-A benzodiazepine site. A network meta-analysis (a pooled comparison of several treatments) found no advantage over placebo (Zhang et al., 2022). Net reading: replicated benefit in trials, unconfirmed in the herb network.

Magnitude: pooled HAM-A mean difference −1.79 points (95% confidence interval, or CI, the range within which the true value most plausibly lies, −3.14 to −0.43) at four weeks, and −1.43 points (95% CI −2.47 to −0.39) at two weeks (Hieu et al., 2019).

Improved Sleep Quality ⚠️ Conflicted

Chamomile improved scores on the Pittsburgh Sleep Quality Index (PSQI, a validated questionnaire where lower scores mean better sleep) in a 28-day randomized trial of 60 nursing-home residents given 200 mg twice daily (Adib-Hajbaghery & Mousavi, 2017) and across five pooled trials (Kazemi et al., 2024). Gains concentrate in staying asleep, not duration or efficiency. A placebo-controlled pilot in 34 adults with chronic primary insomnia found no benefit (Zick et al., 2011). Net reading: consistent benefit for poor sleep quality, no effect once insomnia is established.

Magnitude: pooled PSQI reduction of 1.88 points (95% CI −3.46 to −0.31) across five trials; pooled sleep-quality standardized mean difference (SMD, an effect expressed in standard-deviation units so results from different scales can be combined) −0.73 (95% CI −1.23 to −0.23) in the earlier analysis (Hieu et al., 2019).

Better Blood Sugar Control

Chamomile tea lowered HbA1c (glycated haemoglobin, average blood sugar over about three months), fasting insulin and insulin resistance versus a water regimen in an 8-week randomized trial of 64 adults with type 2 diabetes drinking 3 g in 150 mL three times daily after meals, reported across two papers (Rafraf et al., 2015; Zemestani et al., 2016); a meta-analysis pooled four human trials (Akhgarjand et al., 2024). The proposed mechanism is inhibition of intestinal glucose transport. It was single-blind in one Iranian centre, so blinding failure cannot be excluded.

Magnitude: pooled HbA1c standardized mean difference −0.90 (95% CI −1.39 to −0.40) and fasting glucose −0.65 (95% CI −1.00 to −0.29) across four human trials (Akhgarjand et al., 2024).

Reduced Severity of Cancer-Treatment Mouth Inflammation

Chamomile mouth rinse reduced the severity of oral mucositis and the associated pain across pooled randomized trials (Valmy et al., 2025), a finding echoed by a separate systematic review of chamomile in cancer care (Maleki et al., 2023). The mechanism is local anti-inflammatory and antimicrobial action by the terpenoids and flavones. Trials used differing rinse concentrations, schedules and severity scales, and most were small.

Magnitude: direction is a consistent reduction in mucositis severity and pain, holding where the rinse is started before or at the onset of cancer therapy rather than after ulceration is established; the pooled analyses report statistical significance but no single transferable effect-size figure.

Reduced Dental Plaque and Gum Bleeding

A 1% chamomile mouth rinse cut visible plaque and gum-bleeding scores against placebo over 15 days in a randomized double-blind trial of 30 orthodontic patients (Goes et al., 2016), and chamomile rinse matched 0.12% chlorhexidine (the standard antiseptic mouthwash) for gum bleeding in a separate randomized trial (Batista et al., 2014). The mechanism is local antimicrobial and anti-inflammatory action by the terpenoids and flavones. Both trials were small, short and single-centre, and neither measured bone or gum attachment loss.

Magnitude: visible plaque fell 25.6% and gum bleeding 29.9% from baseline with the chamomile rinse, while the placebo arm rose 10.2% and 23.1% respectively over the same 15 days.

Reduced Symptom Severity in Carpal Tunnel Syndrome

Topical chamomile oil applied to the palmar wrist improved symptom severity and hand function versus placebo oil in a 4-week double-blind randomized trial of 86 adults with mild-to-moderate carpal tunnel syndrome (compression of the median nerve at the wrist, causing hand numbness and pain) (Hashempur et al., 2017), after a pilot trial in severe disease (Hashempur et al., 2015). Both trials came from one research group in one country, and nerve-conduction measures improved less than symptom scores.

Magnitude: direction is improvement in validated symptom-severity and functional-status scores over four weeks of twice-daily topical use, holding in mild-to-moderate rather than surgically indicated disease; the reports give significance but no standardized between-group effect size.

Reduced Menstrual Pain and Bleeding

Chamomile reduced menstrual pain intensity and menstrual bleeding volume in primary dysmenorrhoea (painful periods with no underlying pelvic disease) across seven controlled trials totalling 1,033 participants (Niazi & Moradi, 2021). The proposed mechanism is suppression of prostaglandin and leukotriene production, the same inflammatory messengers that nonsteroidal anti-inflammatory drugs block. Almost all of the trials were small, single-centre and conducted in one country, and the review pooled them narratively rather than statistically.

Magnitude: direction is a fall in menstrual pain intensity and in bleeding volume, holding in primary dysmenorrhoea without pelvic pathology rather than in secondary causes; the review reports consistent direction but no pooled effect-size figure.

Medium 🟩 🟩

Improved Blood Lipids

In the same 8-week single-blind trial of 64 adults with type 2 diabetes, chamomile tea lowered total cholesterol, triglycerides and LDL cholesterol (the cholesterol fraction that drives arterial plaque) against a water control, with no change in HDL cholesterol (the fraction usually described as protective) (Rafraf et al., 2015). The proposed route is reduced intestinal lipid absorption and improved insulin sensitivity. This rests on one trial in one population, and no pooled lipid estimate exists.

Magnitude: direction is a fall in total cholesterol, triglycerides and LDL cholesterol, holding over eight weeks of three daily servings in people with type 2 diabetes; the trial reports statistical significance only and gives no between-group effect size or absolute change.

Reduced Premenstrual Symptom Severity

Chamomile extract reduced premenstrual symptom intensity more than mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID, the ibuprofen class), in a two-cycle randomized trial of 90 students, with the separation confined to the mood component rather than the pain component (Sharifi et al., 2014). The proposed mechanism combines the calming flavone action with cramp-relieving terpenoids. An active comparator without a placebo arm cannot separate drug effect from natural symptom fluctuation.

Magnitude: emotional symptom intensity fell 30.1% and 33.4% across the two treated cycles with chamomile, against 11.6% and 10.7% with mefenamic acid (p < 0.001); the reduction in physical symptoms did not differ between the two.

Reduced Migraine Pain with Topical Use

Topical chamomile oleogel reduced migraine pain, nausea, vomiting and light and sound sensitivity within 30 minutes in a double-blind placebo-controlled crossover trial of 100 adults with migraine without aura (a headache disorder with no preceding visual warning signs) (Zargaran et al., 2018). The preparation was standardized to chamazulene and apigenin, and the proposed route is local anti-inflammatory action by the terpenoids. This is one trial from one research group, with pain recorded on a self-report scale and no replication.

Magnitude: direction is a fall in headache pain and in the accompanying nausea and light and sound sensitivity within 30 minutes of application, holding in migraine without aura rather than in other headache types; the report gives significance levels but no between-group score difference.

Reduced Menopausal Symptom Burden

Oral chamomile standardized to 1.2% apigenin, 100 mg four times daily, lowered total menopausal symptom scores against placebo over 12 weeks in a triple-blind randomized trial of 80 postmenopausal women aged 47 to 62, with separate gains in the vasomotor (hot flush), psychological, locomotor and urological components (Mohsenzadeh-Ledari et al., 2025). The proposed route combines the weak estrogen-like activity of the flavones with their calming action. This is one trial in one centre, and two chamomile participants withdrew with mouth sores, skin spots and itching.

Magnitude: total symptom score fell 10.36 points further than placebo (95% CI −13.84 to −6.92), the largest component being the psychological subscore at −3.74 points (95% CI −5.29 to −2.20).

Reduced Diabetic Nerve-Damage Symptoms

Topical chamomile oil added to standard gabapentin (a prescription nerve-pain medicine) improved validated neuropathy scores against placebo oil in a double-blind randomized trial of 72 adults with diabetic neuropathy (nerve damage from long-standing high blood sugar, causing pain and numbness) (Amiri et al., 2025). Local anti-inflammatory and antioxidant action by the terpenoids is the proposed route. Every participant stayed on gabapentin, so the result describes an add-on effect rather than chamomile alone, and the trial is unreplicated.

Magnitude: adjusted between-group improvements were 1.89 points on the Michigan Neuropathy Screening Instrument, 1.97 points on a validated neuropathic-pain questionnaire and 1.14 units on vibration-threshold testing (p = 0.012).

Low 🟩

Lower All-Cause Mortality Signal in Older Women

Among 1,677 Mexican-origin adults aged 65 and over followed from 2000 to 2007, the 14% who used chamomile had lower mortality, but only women retained the association after adjustment; men showed none (Howrey et al., 2016). Observational, unreplicated and sex-discordant, with confounding by health-seeking behaviour unresolved.

Magnitude: adjusted hazard ratio (the relative rate of death over the follow-up period) 0.72 in women (95% CI 0.53 to 0.98); unadjusted 0.71 overall (95% CI 0.55 to 0.92).

Relief of Functional Indigestion Symptoms

Chamomile is one constituent of the fixed herbal combinations STW 5 (nine extracts) and STW 5-II (six), which relieved functional dyspepsia (persistent upper-abdominal discomfort without structural disease) in pooled analyses (Andresen et al., 2024; Melzer et al., 2004). Chamomile’s own contribution cannot be isolated.

Magnitude: direction is a reduction in dyspepsia symptom scores versus placebo over four to eight weeks of the multi-herb combination; no figure attributable to chamomile alone exists in the literature.

Maintained Remission in Ulcerative Colitis

Chamomile extract is one of three constituents of a myrrh and coffee-charcoal preparation that matched the standard maintenance drug mesalazine for holding remission in ulcerative colitis (colonic inflammation with ulceration) over 12 months in 96 patients (Langhorst et al., 2013). Chamomile’s own contribution cannot be isolated.

Magnitude: relapse over 12 months occurred in 53% of the herbal-preparation arm and 45% of the mesalazine arm, a non-significant difference; the trial tested non-inferiority rather than superiority.

Reduced Severity of Radiotherapy Skin Damage ⚠️ Conflicted

Topical chamomile preparations were tested against active comparators for radiotherapy skin damage. One trial cut grade 2 or worse reactions and sped skin recovery (Garbuio et al., 2022); a larger one found no difference in any-grade incidence (Menêses et al., 2024). Net reading: symptom relief, unproven prevention.

Magnitude: grade 2 or worse skin reactions were less frequent and appeared about seven days later with the chamomile formulation, while any-grade incidence was unchanged at 88.9% in both arms of that trial.

Reduced Depressive Symptoms

Depression scores fell more with chamomile than placebo in an exploratory analysis of the anxiety trial (Amsterdam et al., 2012) and in the 79 open-label subjects with comorbid depression (Amsterdam et al., 2020). A postnatal trial’s gain faded by four weeks (Chang & Chen, 2016). All are secondary endpoints.

Magnitude: direction is a modest fall in clinician-rated depression scores, holding where depression is comorbid with generalized anxiety rather than a primary diagnosis; the exploratory analyses give significance levels only and no between-group score difference.

Reduced Analgesic Need in Knee Osteoarthritis

Topical chamomile oil cut acetaminophen use in a three-week randomized trial against diclofenac and placebo in knee osteoarthritis, while the validated pain, function and stiffness index showed no difference (Shoara et al., 2015). Local anti-inflammatory action is the proposed route. One trial from one research group, unreplicated.

Magnitude: direction is a fall in rescue-analgesic consumption over three weeks of thrice-daily topical use, holding for symptom relief rather than structural change; the trial reports significance only and no figure for analgesic tablets saved.

Faster Healing of Irritated Skin Lesions

Twice-daily German chamomile compresses healed peristomal skin lesions (irritated skin around a surgical bowel opening) faster than 1% hydrocortisone in 72 colostomy patients, with pain and itching settling sooner (Charousaei et al., 2011). Local anti-inflammatory action is the proposed route. Allocation was by matching, not randomization, with no inactive control.

Magnitude: mean time to healing was 8.89 days with chamomile against 14.53 days with 1% hydrocortisone ointment (p = 0.001).

Speculative 🟨

Preservation of the Cell’s Main Energy Coenzyme

Apigenin inhibits CD38 (an enzyme consuming NAD+, a coenzyme central to cell energy that declines with age), raising NAD+ in mice (Escande et al., 2013). Basis is mechanistic animal and cell work only.

Improved Antioxidant-Enzyme and Lipid-Peroxidation Markers

Chamomile tea raised the antioxidant enzymes superoxide dismutase, glutathione peroxidase and catalase (which clear oxidants) and lowered malondialdehyde (a marker of fat oxidation) (Zemestani et al., 2016). These biomarkers are unvalidated; the basis is mechanistic.

Benefit-Modifying Factors

  • Baseline anxiety severity: benefit concentrated in moderate-to-severe generalized anxiety disorder; the trials that enrolled mild cases or non-clinical volunteers for state anxiety found no separation from placebo, so a low starting score leaves little room to move.

  • Baseline sleep pattern: gains appear in people with poor sleep quality but intact sleep drive; the one trial restricted to diagnosed chronic primary insomnia found no benefit on any sleep parameter.

  • Baseline glycemic status: every positive glycemic trial enrolled people with type 2 diabetes and elevated HbA1c. No trial has shown glucose lowering in adults with normal blood sugar, where little movement is expected.

  • Preparation and apigenin content: urinary recovery of apigenin from chamomile tea was roughly three times that from parsley (Borges et al., 2022), and tea infusions run 0.8–1.2% apigenin. Uncharacterised capsules plausibly under-deliver.

  • Sex: the mortality signal held in older women and was absent in men, and the premenstrual and postnatal trials are female-only. Whether the anxiety and glycemic effects differ by sex has not been tested directly.

  • Age: the sleep-quality trials with the clearest effects were in nursing-home residents aged 60 and over, whose baseline sleep is worst; the anxiety trials spanned 18 to 80 with no reported age interaction.

  • Enzyme and transporter variants: apigenin glucuronides are formed by UGT1A enzymes (the UGT family attaches glucuronic acid to compounds so they can be excreted); reduced-function UGT1A variants would raise free apigenin exposure. No chamomile trial has genotyped participants.

  • Pre-existing conditions: the mucositis benefit is defined by active cancer therapy, and the lipid and glycemic benefits by type 2 diabetes. Concurrent inflammatory bowel disease or gastro-oesophageal reflux may alter tolerance of concentrated infusions.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Digestive and Nervous-System Side Effects

Treatment-emergent nausea, dizziness, headache and daytime drowsiness were recorded in the controlled chamomile trials, with one withdrawal for adverse events in each arm of the 8-week trial and comparable low rates across the 26-week continuation trial (Amsterdam et al., 2009; Mao et al., 2016). The pooled analysis found mild adverse events reported in three of twelve trials (Hieu et al., 2019). Drowsiness is mechanistically expected from GABA-A binding. All were mild and reversible on stopping.

Magnitude: the proportion of patients reporting none, one, two, or three or more adverse events did not differ statistically from placebo, and discontinuation for adverse events was one participant per arm out of 57.

Medium 🟥 🟥

No risk reaches Medium: beyond the mild treatment-emergent events graded above, no controlled trial and no consistent body of observational data reports a chamomile-specific harm, leaving uncontrolled case reports, patch-test series and one recall-based cohort as the available evidence.

Low 🟥

Threatened Miscarriage and Preterm Labour with Regular Use in Pregnancy

Among 392 Italian pregnant women interviewed after delivery, regular users of chamomile and liquorice showed more threatened miscarriage and preterm labour (Cuzzolin et al., 2010). The proposed route is uterine-stimulant smooth-muscle activity. One recall-based cohort with no dose data, so causation is unestablished.

Magnitude: direction is a higher incidence of threatened miscarriage and preterm labour, holding for regular rather than occasional use during pregnancy; the study reports the association without hazard ratios or confidence intervals.

Allergic Reactions Including Anaphylaxis

Chamomile tea ingestion has caused anaphylaxis (a sudden whole-body allergic reaction) through cross-reactivity to other Compositae (daisy-family) pollens (Subiza et al., 1989), and a drug monograph contraindicates chamomile in ragweed-pollen hypersensitivity. Risk concentrates in people already sensitized to related pollens. Basis is uncontrolled case reports; reactions can be life-threatening.

Magnitude: direction is a sharply raised risk of immediate hypersensitivity, holding specifically in people with established Compositae or ragweed pollen sensitization rather than in the general population; the reports are individual cases and give no incidence figure.

Increased Bleeding Risk with Anticoagulants

Multiple internal haemorrhages followed chamomile tea and lotion in a patient on the anticoagulant warfarin (Segal & Pilote, 2006); a systematic review of 149 interaction reports lists chamomile among warfarin potentiators (Tan & Lee, 2021). Chamomile’s coumarin content is the proposed route. Evidence is one uncontrolled case report.

Magnitude: direction is a rise in anticoagulant effect and bleeding events, holding when chamomile is added to established warfarin therapy rather than started alongside it; the systematic review reports no pooled risk estimate or clotting-time figure.

Contact Dermatitis and Eye Irritation from Topical Use

Patch testing identified the coumarin herniarin as one sensitizer in German chamomile, explaining delayed eczema from creams and compresses (Paulsen et al., 2010). Chamomile tea used as an eye wash caused conjunctivitis (inflammation of the eye surface) (Subiza et al., 1990). Uncontrolled clinic series only; reactions resolve on withdrawal.

Magnitude: direction is delayed eczematous or conjunctival reaction, holding with repeated skin contact or direct ocular instillation rather than oral use; the patch-test and case series report no incidence figure.

Speculative 🟨

Additive Sedation with Central Nervous System Depressants

Apigenin sedated rats without acting at the benzodiazepine site (Avallone et al., 2000), so additive depression with benzodiazepines, opioids (prescription painkillers), sedating antihistamines (allergy medicines) or alcohol is mechanistically expected. No human study exists.

Reduced Oral Contraceptive Effect and Estrogen-Sensitive Conditions

Weak estrogen-like activity could blunt oral contraceptives and theoretically aggravate hormone-sensitive breast or uterine disease, per a National Institutes of Health fact sheet. Basis is preliminary laboratory work and theory, without clinical confirmation.

Altered Clearance of Drugs Oxidised by Liver Enzymes

Flavones including apigenin inhibit the drug-oxidising enzyme CYP2C9 in vitro (Si et al., 2009), and cyclosporine level changes are proposed in a herb-interaction review. Apigenin clears mainly by conjugation, so clinical relevance is unproven.

Additive Glucose Lowering with Diabetes Medication

Chamomile tea lowered fasting glucose and HbA1c, so additive hypoglycaemia (blood sugar below the safe range) with insulin or insulin-releasing oral medication is plausible. No such event has been reported in any chamomile trial.

Pyrrolizidine-Alkaloid Contamination of Chamomile Products

Surveys found pyrrolizidine alkaloids (liver-toxic compounds from weeds harvested with the crop) in chamomile (Bodi et al., 2014). The basis is product analysis only; no human liver injury has been linked to chamomile.

Risk-Modifying Factors

  • Compositae sensitization: established allergy to ragweed, mugwort, chrysanthemum, marigold, daisy or feverfew is the single largest risk modifier, converting a benign tea into an anaphylaxis hazard through shared pollen allergens rather than a chamomile-specific protein.

  • Anticoagulant and antiplatelet use: warfarin therapy converts chamomile’s coumarin content into a bleeding risk. Direct oral anticoagulants and antiplatelet agents (medicines that keep platelets from clumping) share the theoretical concern without case-level evidence.

  • Pregnancy and breastfeeding: regular use in pregnancy tracked with threatened miscarriage and preterm labour in cohort data, and no lactation safety data exist at all, making both states risk-amplifying.

  • Baseline glucose and diabetes treatment: people already on insulin or sulfonylureas (oral medicines that make the pancreas release more insulin) carry additive hypoglycaemia risk from the same glucose lowering that counts as a benefit in untreated high blood sugar.

  • Baseline clotting markers: an INR (international normalized ratio, a standardized clotting-time measure) already at the upper end of a warfarin target leaves no margin for chamomile’s effect, the setting in which the haemorrhages occurred.

  • Estrogen-sensitive disease: hormone-receptor-positive breast or uterine disease, or reliance on oral contraception, raises the stakes of chamomile’s weak estrogen-like activity even though that activity is unconfirmed clinically.

  • Sex: no trial has reported a sex difference in chamomile’s adverse events, but the pregnancy, contraceptive and estrogen-sensitive risks fall on women alone, while the anaphylaxis and haemorrhage case reports involved both sexes.

  • Conjugation-enzyme variants: reduced-function UGT1A variants would slow apigenin glucuronidation and raise free exposure, plausibly amplifying sedation. No chamomile pharmacogenetic study exists.

  • Age and concurrent sedatives: adults at the older end of the target range carry more sedative co-medication and slower conjugation, so daytime drowsiness and fall risk are the practical concerns rather than the mild nausea seen in younger trial participants.

Key Interactions & Contraindications

  • Vitamin K antagonists (older blood thinners such as warfarin, acenocoumarol and phenprocoumon): caution bordering on avoidance. Documented internal haemorrhage after adding chamomile tea. Mitigation: an INR check at one and two weeks after any change in chamomile intake.

  • Direct oral anticoagulants and antiplatelet agents (apixaban, rivaroxaban, clopidogrel, aspirin): caution, theoretical additive bleeding risk with no case evidence. Mitigation: a two-week hold before planned surgery, as is standard for bleeding-risk supplements.

  • Benzodiazepines, sedative-hypnotics and sedating antihistamines (diazepam, zolpidem, diphenhydramine): caution, additive sedation and impaired alertness. Mitigation: separation from days requiring driving, and a first dose on a non-working evening.

  • Opioids and alcohol (oxycodone, morphine, codeine): caution, additive central nervous system depression. Mitigation: separation from bedtime opioid dosing, and no alcohol on nights chamomile extract is taken.

  • Insulin and insulin-releasing oral medications (sulfonylureas such as gliclazide; meglitinides such as repaglinide): monitor, additive glucose lowering with possible hypoglycaemia. Mitigation: more frequent glucose self-monitoring for two weeks, with prescriber involvement before dose changes.

  • Calcineurin inhibitors (transplant anti-rejection drugs such as cyclosporine and tacrolimus): caution, proposed alteration of drug levels with graft-rejection or toxicity consequences. Mitigation: avoidance unless trough blood levels are being measured.

  • Oral contraceptives and hormone therapy (ethinylestradiol–levonorgestrel tablets, estradiol patches): caution, preliminary evidence of reduced contraceptive effect through weak estrogen-like activity. Mitigation: barrier contraception alongside concentrated extract rather than reliance on chamomile-free intervals.

  • Over-the-counter medication: caution with aspirin and NSAIDs (added bleeding risk), and with sedating cold and allergy products containing diphenhydramine or doxylamine (added drowsiness). Mitigation: substitution of a non-sedating antihistamine.

  • Supplement interactions: caution with other anticoagulant-potentiating supplements such as fish oil, vitamin E, ginkgo, garlic and curcumin, which add to bleeding risk. Mitigation: no more than one at therapeutic dose.

  • Additive-effect supplements: monitor. Valerian, passionflower, kava, lemon balm, magnesium, glycine and L-Theanine all add sedation and daytime impairment, and berberine, cinnamon and chromium add glucose lowering with hypoglycaemia risk. Mitigation: one agent added at a time.

  • Other interventions: caution with topical chamomile alongside other Compositae botanicals (arnica, calendula, feverfew), which raises cumulative sensitization risk. Mitigation: a 48-hour patch test on a small skin area first.

Populations who should avoid Chamomile:

  • Anyone with confirmed hypersensitivity to chamomile or to ragweed pollen, an absolute contraindication in drug references, and anyone with prior anaphylaxis to any Compositae plant
  • Pregnancy at any stage, and specifically regular use before 37 weeks’ gestation, given the threatened-miscarriage and preterm-labour signal
  • Breastfeeding, on the basis of absent data rather than demonstrated harm
  • Patients on warfarin whose INR is unstable or running above the upper limit of their prescribed target
  • Solid-organ transplant recipients on anti-rejection drugs without therapeutic drug monitoring in place
  • Anyone within two weeks of elective surgery or spinal or epidural anaesthesia
  • People with active hormone-receptor-positive breast or endometrial disease, as a precaution rather than a documented harm

Risk Mitigation Strategies

  • Compositae allergy screen before first use: a direct question about ragweed, mugwort, chrysanthemum, marigold, daisy or feverfew reactions, and about prior anaphylaxis, identifies the population in whom the single severe risk concentrates.

  • First-dose caution with a single cup: starting with one weak infusion in a setting where help is available, rather than a 1,500 mg extract, limits exposure if an unrecognised immediate hypersensitivity reaction occurs.

  • Topical patch test at 48 hours: applying chamomile oil or cream to a coin-sized area of forearm skin for two days before wider use detects herniarin-driven contact dermatitis before a whole-limb reaction develops.

  • No ocular use: using commercial sterile eye products rather than cooled tea as an eye wash avoids the allergic conjunctivitis reported from direct ocular instillation.

  • INR recheck at one and two weeks: in warfarin users, clotting is rechecked at those two points after chamomile is started or stopped, which is when the reported haemorrhagic case became apparent.

  • Two-week washout before surgery: stopping chamomile fourteen days before elective procedures or spinal or epidural anaesthesia removes the additive bleeding contribution during and after surgery.

  • Glucose self-monitoring for two weeks: users of insulin or insulin-releasing oral medication test more often for the first fortnight after adding chamomile, which catches additive hypoglycaemia before it becomes symptomatic.

  • Evening-only dosing at first: taking the extract 30–60 minutes before bed on a non-working evening confines the expected drowsiness to a period where impaired alertness carries no consequence.

  • A tested, alkaloid-screened product: selecting a brand with third-party certification and published pyrrolizidine-alkaloid results addresses the contamination found in surveys of chamomile teas.

  • Pre-conception discontinuation: discontinuing before attempting pregnancy avoids the threatened-miscarriage and preterm-labour signal without needing to resolve whether that association is causal.

Therapeutic Protocol

  • Standardized extract, the trial regimen: 500 mg of pharmaceutical-grade Matricaria chamomilla extract three times daily, totalling 1,500 mg, as used in the 12-week open-label and 26-week continuation phases of the University of Pennsylvania programme.

  • Titration used in the original trial: the 2009 trial started at 220 mg daily and escalated weekly by 220 mg to a maximum of 1,100 mg (Amsterdam et al., 2009), the gentler alternative for sedation-sensitive users.

  • Tea preparation: 3 g of dried flowers in 150 mL of just-boiled water, three times daily immediately after meals, is the regimen that produced the glycemic and lipid results.

  • Apigenin-led dosing, the alternative approach: isolated apigenin at 50 mg before bed is the approach popularised through the Huberman Lab sleep protocol; it targets one constituent rather than the whole extract and has no trial behind it.

  • Topical oil: 1% chamomile oil standardized to about 0.227 mg/g apigenin, applied to the palmar wrist twice daily for four weeks, is the carpal tunnel regimen.

  • Mouth rinse: roughly 8 g of flowers infused in 1,000 mL of water, used as a gargle, is the concentration used in mucositis trials, started before or at the onset of cancer therapy.

  • Best time of day: evening for the anxiety and sleep uses, 30–60 minutes before bed; immediately after meals for the glycemic use, where after-meal glucose uptake is the target.

  • Half-life and duration: the tea’s apigenin-4’-glucuronide peaks near two hours and is largely cleared within 24 hours, which is why trials used three daily doses rather than one.

  • Single versus split dosing: split three times daily for anxiety and glycemic goals, matching the short exposure window; a single evening dose is the pattern used for sleep, where night-time coverage is all that is needed.

  • Genetic variants: reduced-function UGT1A variants slow apigenin conjugation and favour the lower end of the range; variants in COMT (which clears dopamine) and CYP2C19 (a drug-oxidising enzyme) have not been tested with chamomile.

  • Sex-based differences: no dose difference is established. The mortality association appeared only in women, and the premenstrual regimen is female-specific, but the anxiety and glycemic trials enrolled both sexes without reported interaction.

  • Age-related adjustment: the sleep trials in residents aged 60 and over used only 200 mg twice daily, a quarter of the anxiety dose, so the trial-validated dose at the older end of the range is the lower one.

  • Baseline biomarkers: an elevated HbA1c or fasting insulin marks the group in whom glycemic benefit was demonstrated; a normal result predicts little movement and argues for the sleep or anxiety indication instead.

  • Pre-existing conditions: moderate-to-severe generalized anxiety and type 2 diabetes are the conditions in which the regimens above were validated; reflux or inflammatory bowel disease may require the extract rather than three large infusions.

Discontinuation & Cycling

  • Not intended as lifelong therapy: the longest controlled exposure is 38 weeks across both phases of the relapse-prevention trial (Mao et al., 2016). Nothing establishes benefit or safety beyond that.

  • Withdrawal effects: discontinuation-emergent signs and symptoms were formally measured when chamomile was switched to placebo in the continuation trial and were similar between arms, so no withdrawal syndrome has been demonstrated.

  • Relapse rather than withdrawal: among trial responders switched off chamomile, 25.5% relapsed versus 15.2% who continued, with mean time to relapse 6.3 versus 11.4 weeks (Mao et al., 2016).

  • Tapering: no taper is indicated by the evidence, since abrupt substitution produced no discontinuation signal. No trial has tested a stepped reduction, including in people on concurrent sedatives.

  • Cycling not established: no trial has compared continuous with intermittent chamomile. Tolerance has not been reported, and the 26-week continuation arm retained its symptom advantage, which argues against a need to cycle.

  • Stopping before specific events: the intervention is stopped entirely, not tapered, two weeks before elective surgery and before attempting pregnancy, and immediately on any suspected allergic reaction.

Sourcing and Quality

  • Species matters: German chamomile (Matricaria chamomilla) is the species in essentially all clinical trials; Roman chamomile (Chamaemelum nobile) has a different essential-oil profile and almost no trial evidence, yet both are sold as “chamomile”.

  • Standardization to apigenin: the trial-grade material was standardized to 1.2% apigenin. Products that state only total flower weight, or no marker at all, cannot be mapped onto the doses used in the trials.

  • Third-party testing: certification from an independent laboratory such as USP, NSF or Eurofins, which verify identity and contaminant limits, is the practical proxy for the pharmaceutical-grade extract used in the trials.

  • Pyrrolizidine-alkaloid screening: chamomile carried some of the highest alkaloid loads in European tea surveys (Bodi et al., 2014). A published alkaloid result, or compliance with the European limit, is the specific test that addresses this.

  • Heavy metals and pesticides: chamomile is a low-growing crop harvested whole, which makes soil-borne metals and residue carry-over plausible. Certificates of analysis covering lead, cadmium and pesticide residues address this.

  • Tea versus capsule: loose flower heads brewed covered retain more volatile oil than dust-grade tea bags, and the tea route has the glycemic evidence, while the capsule route has the anxiety evidence.

  • Reputable suppliers: the German phytomedicine manufacturers behind the fixed multi-herb dyspepsia preparations, and compounding pharmacies working to pharmacopoeial monographs, are the sources that document apigenin content rather than estimating it.

Practical Considerations

  • Time to effect: anxiety scores separated from placebo within two to four weeks; sleep-quality gains appeared by two weeks and consolidated by four; glycemic and lipid changes required the full eight weeks of dosing.

  • Pitfall, wrong species or unstandardized product: buying Roman chamomile or a tea-bag blend without an apigenin figure is the commonest way to take a dose that bears no relation to the trials.

  • Pitfall, under-dosing: a single evening cup is roughly a ninth of the daily flower weight used in the glycemic trials and a fraction of the 1,500 mg extract used for anxiety.

  • Pitfall, ignoring the allergy question: treating a herbal tea as risk-free is the error behind the anaphylaxis reports, all of which occurred in people already sensitized to related pollens.

  • Pitfall, stacking sedatives: combining chamomile with valerian, magnesium, glycine and an antihistamine at once makes both benefit and any daytime sedation impossible to attribute.

  • Regulatory status: in the United States chamomile is a dietary supplement under the Dietary Supplement Health and Education Act, not reviewed for efficacy before sale; in Germany the flower is an approved Commission E herbal medicine for specified inflammatory and spasmodic indications.

  • Cost, accessibility and payer incentives: chamomile is inexpensive and unrestricted, while generic sedatives and antidepressants are cheap and reimbursed. No patent holder gains from large chamomile trials and no insurer saves by funding them, which is a structural reason the evidence base stayed small.

Interaction with Foundational Habits

  • Sleep: direct and potentiating. Flavone action at the brain’s main inhibitory receptor is the mechanism, and gains are in staying asleep rather than falling asleep or total duration. Practical point: the extract was given 30–60 minutes before bed, and little is expected once sleep hygiene is already optimal, since the insomnia trial was null.

  • Nutrition: direct and dose-shaping. Absorption of chamomile’s apigenin glucoside occurs in the upper gut, roughly three times more efficient than from parsley (Borges et al., 2022), and the glycemic trials dosed after meals to target after-meal glucose uptake. Practical point: dosing with food matches the trials, and no evidence shows chamomile depletes any nutrient.

  • Exercise: indirect. No trial has measured chamomile’s effect on training adaptation, strength or endurance, and no mechanism predicts blunted hypertrophy since the flavones are not antioxidant-dose vitamins. Practical point: evening dosing keeps the expected drowsiness away from training sessions, and the topical oil has only wrist-specific evidence, not general recovery data.

  • Stress management: direct. The anxiety-reducing effect is the intervention’s best-evidenced action, and an exploratory study found altered salivary cortisol patterns during chamomile treatment of generalized anxiety (Keefe et al., 2018), though not as a primary endpoint. Practical point: chamomile was tested as sole therapy, not alongside structured stress interventions, so their combined effect is untested.

Monitoring Protocol & Defining Success

Before starting, the useful baseline depends on which claim is being pursued. For the glycemic and lipid indications it is HbA1c, fasting glucose, fasting insulin and a full lipid panel, since those are the outcomes the trials moved. For the anxiety and sleep indications it is a starting score on a validated instrument rather than an impression. For anyone on warfarin, a stable INR comes first. A daisy-family allergy screen precedes the first dose. A single baseline of liver enzymes is relevant because conjugation is the clearance route.

Ongoing testing follows the timelines in which effects appeared: the chosen symptom score is repeated at 2 and 4 weeks, INR is rechecked at 1 and 2 weeks after starting or stopping, and the glycemic, lipid and liver panels are repeated at 8 to 12 weeks, then every 6 to 12 months where use continues.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
HbA1c ≤5.4% Tracks the average blood sugar chamomile is claimed to lower Conventional “normal” extends to 5.6%; no fasting needed; pair with fasting insulin
Fasting glucose 75–85 mg/dL Baseline for the glycemic claim and for additive lowering with diabetes drugs Conventional reference runs to 99 mg/dL; 8–12 hour fast; morning draw
Fasting insulin ≤5 µIU/mL Chamomile tea lowered insulin and insulin resistance in the diabetes trials Conventional reference runs to about 25 µIU/mL; combined with glucose to compute HOMA-IR, a calculated index of insulin resistance; 8–12 hour fast
Lipid panel Triglycerides <80 mg/dL; LDL cholesterol set by individual risk The lipid fractions that fell in the chamomile tea trial Conventional triglyceride cut-off is 150 mg/dL; 8–12 hour fast; best paired with the glucose draw
hs-CRP <0.5 mg/L Cheapest readout of the anti-inflammatory claim hs-CRP is high-sensitivity C-reactive protein, a general inflammation marker; conventional low-risk band is <1.0 mg/L; not drawn within 2 weeks of infection
INR The individual’s own prescribed warfarin target Detects the anticoagulant potentiation reported with chamomile Relevant only to vitamin K antagonist users; checked at 1 and 2 weeks after any change in chamomile intake
ALT and AST ALT ≤20 U/L in women, ≤25 U/L in men Baseline liver status, given alkaloid contamination reports and conjugative clearance ALT and AST are liver enzymes released when liver cells are stressed; conventional upper limits run to about 40 U/L; morning draw, no strenuous exercise beforehand
Compositae-specific IgE No established target; used qualitatively as present or absent Confirms the daisy-family sensitization behind the anaphylaxis reports IgE is immunoglobulin E, the antibody class behind immediate allergy; relevant only where allergy is suspected, and skin-prick results are tracked rather than a numeric goal

Qualitative markers worth tracking alongside the labs:

  • Sleep continuity, specifically the number of night-time awakenings, which is where the pooled sleep benefit concentrated
  • Time to fall asleep, improved in three of four trials that measured it (Kazemi et al., 2024)
  • Daytime alertness and absence of morning sedation, the practical signal that the dose is too high or too late
  • Subjective worry intensity and its intrusiveness during the day
  • Post-meal fullness, bloating and upper-abdominal discomfort
  • Absence of any itching, rash, lip or throat tingling, which is the stop signal

Emerging Research

  • Chamomile alone versus placebo for dental anxiety: NCT07138391 is a phase 2/3 randomized trial of chamomile gummies against multivitamin placebo in 78 children, with pulse rate and a dental anxiety scale as endpoints. Paediatric, so it tests the compound rather than this review’s population.

  • Chamomile inside an adult sleep blend: NCT07298161 is a recruiting 30-day single-arm study of 100 adults taking a chamomile-containing sleep drop, with a validated sleep-disturbance scale as the primary endpoint. Industry-sponsored and uncontrolled, so it cannot strengthen the case.

  • Chamomile with L-Theanine for period pain: NCT07092878 is recruiting 30 young women with primary dysmenorrhoea (period pain) for a beverage carrying 480 mg chamomile extract, with pain intensity as primary endpoint. Beverage-company funded, and the combination design will not isolate chamomile.

  • Multi-herb chamomile preparation on the gut lining: NCT07198243 is a phase 4 randomized trial in 100 adults with functional dyspepsia whose primary endpoint is duodenal eosinophil count, the immune-cell measure that symptom-only dyspepsia trials have never provided.

  • Whether apigenin raises NAD+ in people: the CD38-inhibition result of Escande et al., 2013 is mouse and cell work. No human study has measured tissue NAD+ after chamomile, and a null human result would remove the main longevity rationale rather than strengthen it.

  • Whether realistic doses reach active concentrations: Borges et al., 2022 recovered 34% of chamomile-tea apigenin intake in urine, far above parsley. Dose-ranging pharmacokinetic work could validate the tea route or expose the capsule route as under-delivering.

  • Whether the anxiety signal survives replication: the negative network meta-analysis of Zhang et al., 2022 and the null insomnia pilot of Zick et al., 2011 both argue that an adequately powered independent trial could weaken, not confirm, the current picture.

Conclusion

Chamomile is a daisy-family flower, taken as tea, as a measured oral extract, as a mouth rinse or as a topical oil, whose effects are attributed to a mixture of plant pigments and aromatic oils rather than one active compound. The strongest human findings are modest reductions in persistent anxiety, better-rated sleep quality in people who sleep poorly, lower average blood sugar in people with type 2 diabetes, less painful mouth inflammation during cancer treatment, less dental plaque and gum bleeding, and less menstrual pain. Each of those rests on small trials, and for anxiety and sleep the combined trial evidence points both ways.

The main hazards are narrow but real: immediate allergic reactions in people already allergic to related plants, added bleeding when combined with blood-thinning medication, and a pregnancy signal that has not been explained away. Mild nausea and daytime drowsiness are common and reversible.

The evidence base is unusually free of manufacturer influence, because there is nothing in a common flower to patent. That cuts the other way too: no commercial sponsor has reason to fund large trials, and none has, while the professional-society bodies that have weighed in carry their own ties to conventional alternatives. For someone already optimizing sleep, blood sugar and stress, chamomile sits at the low-cost, low-risk, low-certainty end of the available options.

Top - Benefits - Risks - Protocol